Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iroko Pharmaceuticals has launched Tivorbex (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), in the US for the treatment of acute pain.
Subscribe to our email newsletter
Currently, Tivorbex capsules are now available by prescription at pharmacies across the country.
Tivorbex 20mg and 40mg dosage strengths are 20% lower than the 25mg and 50mg indomethacin products currently on the market.
The US Food and Drug Administration (FDA) has approved Tivorbex for the treatment of mild to moderate acute pain in adults.
Iroko president Lou Vollmer said: "Tivorbex joins Zorvolex (diclofenac) capsules, a low dose formulation of diclofenac, in our growing portfolio and signifies Iroko’s commitment to developing low dose NSAID options for patients."
Iroko Pharmaceuticals chief medical officer Dr Clarence Young added: "Tivorbex has demonstrated significant pain relief at the lowest dose of indomethacin available, and this launch brings us another step further in addressing the need for efficacious, yet low dose, NSAID treatment options for pain management."
Tivorbex contains indomethacin as submicron particles that are about 20 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution.